Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ironwood Pharmaceuticals, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Must not be pregnant or breastfeeding and agree to use birth control;
Completion of a negative colonoscopy as per American Gastroenterology Association (AGA) criteria and no clinically-significant laboratory or physical examination findings;
Meets protocol-defined criteria for IBS-C, including stool frequency, straining, stool consistency, abdominal pain, and abdominal discomfort criteria;
Demonstrates English fluency and has access to a touch-tone telephone.
You may not be if
Recent history of mushy or watery stools;
Various medical conditions, medical histories, or family medical histories that would not make the patient a good candidate for the study;
Clinically-significant alarm symptoms;
Secondary causes of constipation or evacuation disorders;
Surgery to the gastrointestinal tract;
Usage of prohibited medications.
Clareo Health | Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
